ArticleThe American journal of gastroenterology2026

Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.

Marie André et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.